Brief: PTC Completes Acquisition Of St-920 Fabry Disease Gene Therapy
21/09/2026 22:02
BRIEF-PTC Completes Acquisition Of St-920 Fabry Disease Gene Therapy Sept 22 (Reuters) - PTC Therapeutics, Inc. PTCT.O:
PTC COMPLETES ACQUISITION OF ST-920 FABRY DISEASE GENE THERAPY
PTC THERAPEUTICS, - EXPECTS ST-920 BLA SUBMISSION TO FDA COMPLETED IN Q4 2026
Source text: ID:nPn8LsSw9a
Further company coverage: PTCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PTC Therapeutics
See all newsBrief: PTC Completes Acquisition Of St-920 Fabry Disease Gene Therapy
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: PTC To Expand Rare Disease Portfolio With Acquisition Of BLA-Stage St-920 Fabry Disease Program
PTC Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
PTC Therapeutics Q2 revenue more than doubles, raises 2026 outlook